News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2013

10 December, 2013 First patient treated in part 2 of the PLIANT-study News English IR Optional
13 November, 2013 Go-ahead for PledPharma to start part 2 of the PLIANT study News English IR Optional
25 October, 2013 Interim Report Third Quarter 2013 News English Report Interim Q3 IR Optional
29 August, 2013 Interim Report Second Quarter 2013 News English Report Interim Q2 IR Optional
24 May, 2013 Rights issue in PledPharma oversubscribed News English IR Optional
18 April, 2013 Interim Report First Quarter 2013 News English Report Interim Q1 IR Optional
3 April, 2013 PledPharma AB (publ) issues new shares News English IR Optional
21 February, 2013 PledPharma AB (publ) Full Year Report 2012 News English Report Interim Yearend IR Optional
20 February, 2013 PledPharma's patent application approved and issued in USA News English IR Optional
12 February, 2013 First patient included into PledPharma’s PLIANT study News English IR Optional
30 January, 2013 PLIANT study starts in the U.S. News English IR Optional
9 January, 2013 Nortal Investments Acquires Additional Shares in PledPharma News English IR Optional

Calendar and upcoming reports

May 3, 2024
Interim Report Q1 2024 (7:00am CEST)

May 6, 2024
Annual General Meeting

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com